drugset
drugset / Trial / NCT05748119

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

NCT05748119 ↗

Phase 1 Unknown 72 enrolled Mebias Discovery, Inc
RandomizedSequentialDouble-blindTreatment

Summary

Primary Objective: To determine the safety and tolerability of single and multiple ascending oral doses of MEB-1170 in healthy subjects. Secondary Objectives: 1. To determine the single and multiple oral dose pharmacokinetic profiles of MEB-1170 and the primary metabolite, M373, in healthy subjects. 2. To determine the effect of food on the pharmacokinetic (PK) profile of a single oral dose of MEB-1170 in healthy subjects. 3. To assess the pharmacodynamic (PD) response following single and multiple oral doses of MEB-1170

Timeline

Start
2022-11-15
Primary completion
2023-10-01
Completion
2023-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MEB-1170 Unknown 20 mg Oral
Subject MEB-1170 Unknown 60 mg Oral
Subject MEB-1170 Unknown 100 mg Oral
Subject MEB-1170 Unknown 120 mg Oral
Subject MEB-1170 Unknown 200 mg Oral
Subject MEB-1170 Unknown 400 mg Oral

Indications

No indication recorded.